US Pharma MarketingValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccines
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs. Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events…
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
Source: FierceBiotech